Showing 381-390 of 5059 results for "".
- BioFactura Starts Phase I Study of BFI-751, a Stelara Biosimilarhttps://practicaldermatology.com/news/biofactura-starts-phase-i-study-of-bfi-751-a-stelara-biosimilar/2460811/BioFactura is set to begin a pivotal pharmacokinetics Phase 1 clinical trial for its Ustekinumab biosimilar BFI-751. The first-in-human Phase I study will assess the effects on healthy human volunteers compared to the biologic medicine, Stelara. This is the first time BFI-751 has been a
- Medivir’s Remetinostat Shows Promise for SCChttps://practicaldermatology.com/news/medivirs-remetinostat-shows-promise-for-scc/2460807/Topical remetinostat gel performed well in a small investigator-initiated phase II clinical study of patients with squamous cell carcinoma. Four patients with five cutaneous SCCs were included in this case series and treated with remetinostat gel 1%. All five tumors, including
- Arcutis to Present New Data for Roflumilast in PsO at EADVhttps://practicaldermatology.com/news/arcutis-to-present-new-data-for-roflumilast-in-pso-at-eadv/2460798/New data from the DERMIS-1 and DERMIS-2 pivotal phase 3 studies evaluating roflumilast cream (ARQ-151) show that the investigational once daily, topical PDE4 inhibitor for psoriasis achieved the primary efficacy endpoint of IGA success at week eight for chronic plaque psoriasis. Data are being pr
- Snacking on Almonds May Smooth Wrinkles, Reduce Dark Spotshttps://practicaldermatology.com/news/snacking-on-almonds-may-smooth-wrinkles-reduce-dark-spots/2460717/Snacking on almonds may help reduce wrinkles and skin pigmentation in postmenopausal women, according to a new study funded by the Almond Board of California. In this 6-month randomized controlled trial, 49 healthy postmenopausal women with Fitzpatrick skin type 1 or 2 were randomly ass
- Vyne Therapeutics to Move Forward with Topical Tofacitinib/Fingolimod Gel for ADhttps://practicaldermatology.com/news/vyne-therapeutics-to-move-forward-with-topical-tofacitinibfingolimod-gel-for-ad/2460707/Vyne Therapeutics Inc. plans to move forward on development of its fixed combination of pan-JAK inhibitor tofacitinib and sphingosine 1-phosphate receptor modulator fingolimod in a topical gel for mild-to-moderate atopic dermatitis. A phase 2a proof of concept study for FMX114 is planned to start
- Dermavant: Promising Interim Analysis from Third Phase 3 Trial for Tapinarof in Psoriasishttps://practicaldermatology.com/news/dermavant-promising-interim-analysis-from-third-phase-3-trial-for-tapinarof-in-psoriasis/2460693/Positive results from a planned interim analysis of PSOARING 3, Dermavant Sciences’ long-term, open-label safety study, show that approximately 40 percent of subjects treated with investigational tapinarof cream, 1% achieved complete disease clearance (PGA score = 0). Treatment was well tol
- Skyrizi Performs Well in Phase 3 Studies of PsAhttps://practicaldermatology.com/news/skyrizi-performs-well-in-phase-3-studies-of-psa/2460647/Two Phase 3 studies of Risankizumab (Skyrizi) show improvements in disease activity across joint and skin symptoms in patients with psoriatic arthritis. KEEPsAKE-1 and KEEPsAKE-2 found that significantly more patients treated with risankizumab (150 mg) achieved the primary end
- More Positive Phase 3 Data for Pfizer's Abrocitinib in ADhttps://practicaldermatology.com/news/more-positive-phase-3-data-for-pfizers-abrocitinib-in-ad/2460607/Positive top-line results from the phase 3 JADE REGIMEN study offer additional data in support of Pfizer's investigational oral once-daily Janus kinase 1 (JAK1) inhibitor for atopic dermatitis (AD). The 52-week study looked at patients 12 and older wi
- Tremfya Reduces Fatigue in PsAhttps://practicaldermatology.com/news/tremfya-reduces-fatigue-in-psa/2460602/The IL-23 blocker Tremfya (guselkumab) improves fatigue in adult patients with active psoriatic arthritis (PsA) and this response is maintained through 52 weeks of active treatment, according to data from two Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2. Tremfya improved
- Ilumya Shows 5-Year Sustained Efficacy and Safety in Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/ilumya-shows-5-year-sustained-efficacy-and-safety-in-moderate-to-severe-plaque-psoriasis/2460596/Patients with moderate-to-severe plaque psoriasis who continued to receive Ilumya (tildrakizumab-asmn) through five years of continuous treatment maintained consistent and extensive skin clearance with no new safety signals, according to Phase 3 data from the combined reSURFACE 1 and reSURFACE 2